newsfilter
← Earnings
Earnings Releases·

AN2 Therapeutics — Third Quarter 2026 Earnings Summary

  • Net loss narrowed to $8.0 million from $9.4 million in Q3 2025, driven by a 13% reduction in total operating expenses to $8.7 million, while cash, cash equivalents, and investments totaled $80.2 million.
  • Existing capital resources are projected to sustain operations into 2029 under the current operating plan.
  • Regulatory clearance received to initiate a global Phase 2 study of epetraborole in polycythemia vera (PV) by end of 2026, with Part 1 data expected in 2027.
  • Pipeline progress includes the selection of AN2-504661 as the development candidate for hypophosphatasia (HPP) with a Phase 1 study planned for late 2027, and ongoing enrollment for the M. abscessus Phase 2 trial.
  • No revenue was reported for the quarter, consistent with the company's clinical-stage status.
Company
AN2 THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology